BrainStorm Cell Therapeutics Inc. Chief Scientist, Dr. Daniel Offen, To Present Results from New Parkinson's Study at International Stem Cell Meeting in Tel Aviv

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that Dr. Daniel Offen, the Company’s Chief Scientist, will present results of a most recent study in the Parkinson’s disease project, under the title: “HUMAN BONE MARROW STEM CELLS INDUCED TO SECRETE NEUROTROPHIC FACTORS AS A NEW STRATEGY FOR AUTOLOGOUS CELL THERAPY IN NEURODEGENERATIVE DISEASES”, the lecture will be given at the Second International Stem Cell Meeting: “The Potency of Stem Cells” to be held from May 27-29, 2008 in Tel-Aviv in conjunction with the ILSI-Biomed Israel 2008 Conference.